Lucem Health

What Lucem Health does

Lucem Health is a privately held healthcare AI company founded in 2021 in Raleigh, North Carolina, that builds AI-powered early disease detection software for U.S. healthcare providers and life sciences companies. The core product, Lucem Health Reveal, analyzes existing electronic health record data—including demographic, laboratory, medication, comorbidity, and encounter information—using validated clinical machine learning models to identify patients at higher statistical risk for undiagnosed serious diseases. The platform comprises disease-specific modules covering arrhythmias, atrial fibrillation–related stroke, colorectal cancer, lung cancer, liver disease (MASLD/MASH), and Type 1 diabetes, and is designed to integrate into existing clinical workflows without requiring process changes.

The company monetizes through enterprise subscriptions from health systems, hospitals, accountable care organizations, and integrated delivery networks, and through its Life Sciences Accelerate Program and Disease Insights module, which provide pharma and medical device partners with AI-driven post-market patient identification and market-access analytics. Distribution is sales-led and direct, supplemented by strategic channel partnerships with device and pharmaceutical companies such as iRhythm Technologies and Sanofi, and the company is co-founded with Mayo Clinic, which serves as both an investor and reference customer alongside Mercy Hospital St. Louis. Validation data is cited across 14M patient records and 442M encounters, with reported performance advantages such as up to 8x colorectal cancer detection, 47x Type 1 diabetes screening efficiency, and 3x liver disease screening efficiency versus standard approaches.

The business is at an early commercial stage: roughly $10M in total disclosed funding ($7.7M in May 2023 led by Granger Management and Mayo Clinic with Rally Ventures, plus $2.3M in August 2025), 11–50 employees, SOC 2 Type 2 compliance, and recognition including the 2025 Digital Health Hub Rising Star for AI in Health Operations. Revenue is not publicly disclosed, pricing is not listed, and only two enterprise customers are named, indicating the company is in early commercialization despite a mature product surface and validated clinical claims.

Name

Lucem Health

Legal name

Lucem Health

Website

https://lucemhealth.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Clinical Decision Support AI

NAICS

Other Computer Related Services (541519)

SIC

Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Quality Measurement, Reporting & Benchmarking (HEDIS/Stars/CQM) (HLACAHAC)

Keywords

• Clinical AI platform
• Early disease detection
• EHR risk prediction
• Healthcare analytics software
• Patient identification AI

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Healthcare Provider Subscriptions: Subscription-based revenue from healthcare provider organizations accessing Reveal early disease detection programs. Providers pay for AI-powered solutions that improve patient outcomes and deliver ROI.
2. Life Sciences Partnerships: Revenue from life sciences companies participating in the Accelerate Program, which helps partners expand market opportunities and optimize market access strategies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Lucem Health develops and sells an AI-powered early disease detection platform (Lucem Health Reveal) that analyzes existing electronic health record (EHR) data using validated clinical machine learning models to identify patients at higher statistical risk for serious undiagnosed diseases such as arrhythmias, colorectal cancer, liver disease, lung cancer, stroke, and Type 1 diabetes. The platform is sold to healthcare providers (health systems, hospitals, ACOs) and to life sciences companies via a complementary Disease Insights analytics offering and the Accelerate Program.

Product overview

Lucem Health offers a unified platform-plus-modules architecture centered on its core Lucem Health Reveal early disease detection platform. Reveal is powered by validated clinical AI models that analyze existing EHR data to identify patients at higher statistical risk for undiagnosed diseases. The platform includes disease-specific sub-products: Reveal for Arrhythmias, Reveal for Colorectal Cancer, Reveal for Liver Disease, Reveal for Lung Cancer, Reveal for T1D, and Reveal for Stroke. Complementing Reveal is the Disease Insights add-on module for life sciences companies, which provides market access analytics including diagnostic pathways, provider trends, and patient outcomes data. The Accelerate Program enables life sciences partners to expand patient access through the Reveal solutions.

Differentiator

Problem solved

Functional benefit

Brands

• Reveal: AI-powered early disease detection platform that surfaces patients at higher risk of serious diseases before they become life-threatening. Includes solutions for arrhythmias, colorectal cancer, liver disease, lung cancer, stroke, and Type 1 Diabetes.
• Reveal for Arrhythmias
• Reveal for Colorectal Cancer
• Reveal for Liver Disease
• Reveal for Lung Cancer
• Reveal for T1D
• Disease Insights
• Accelerate Program

Products and services

• Lucem Health Reveal AI-powered early disease detection platform that analyzes existing EHR data to identify patients at higher statistical risk for serious undiagnosed diseases, enabling proactive care delivery programs without requiring workflow changes. Sold to healthcare providers and life sciences companies.
• Reveal for Arrhythmias AI solution that identifies patients at elevated risk for arrhythmias by analyzing EHR data, targeting populations with comorbid conditions such as Type 2 diabetes, chronic kidney disease, COPD, and coronary artery disease; integrates with iRhythm's Zio ECG monitoring.
• Reveal for Colorectal Cancer AI-powered early detection solution that identifies patients at higher statistical risk for colorectal cancer and other lower GI disorders, achieving up to 8x improved detection rates versus standard approaches.
• Reveal for Liver Disease AI-enabled solution that sifts through EHRs to identify individuals at higher statistical risk of undiagnosed MASLD or MASH by analyzing demographic, laboratory, medication, and comorbidity data; achieves 3x improved liver disease detection.
• Reveal for Lung Cancer AI solution that analyzes existing EHR data to identify patients showing higher statistical risk of lung and trachea cancers, enabling earlier screening and intervention for at-risk populations.
• Reveal for T1D AI and EHR-based solution to identify early-stage Type 1 Diabetes before DKA onset, achieving up to 47x improved screening efficiency; backed by Sanofi partnership.
• Reveal for Stroke AI solution designed to identify patients with undiagnosed atrial fibrillation (AFib) and higher risk of AFib-related strokes by analyzing ECG and EHR data.
• Disease Insights

Quantifiable outcome

• Up to 8x improved colorectal cancer detection
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

Partnerships

Three partnerships are on record, tiered core.

• iRhythm TechnologiescoreStrategic or Co-development Partner · 31 July 2025Strategic partnership combining Lucem Health's Reveal for Arrhythmias analytics with iRhythm's proven Zio ECG technology. The integration creates a seamless solution designed to shift cardiac care from reactive diagnosis to predictive, data-driven intervention. iRhythm's Zio device provides extended ambulatory cardiac monitoring capable of up to 14 days of continuous data collection, powered by an FDA-cleared AI algorithm. The joint commercial offering is designed for integration into ACO and health system workflows committed to value-based care.
• Mayo CliniccoreStrategic or Co-development PartnerCo-founding partner of Lucem Health. The company was founded with Mayo Clinic and has developed its clinical AI platform in partnership with the renowned healthcare institution. Mayo Clinic Platform serves as a trusted customer and reference for the company's solutions. John Halamka, M.D., President of Mayo Clinic Platform, has provided endorsement: 'the development of AI and machine learning algorithms has the potential to revolutionize diagnostic medicine – and Lucem Health is paving the way.'
• SanoficoreStrategic or Co-development PartnerBacker of Lucem Health's Reveal for T1D initiative launched in September 2025. Sanofi provided support for the development of AI-powered early detection of Type 1 Diabetes using EHR data to identify early-stage T1D, helping reduce preventable DKA and improve follow-up care.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Medial EarlySign: Medial EarlySign develops AI models that analyze EHR data to identify patients at risk of undiagnosed disease, including oncology and metabolic conditions — a directly comparable early-detection AI approach. Lucem Health already collaborates with EarlySign on data science roundtables, underscoring product overlap.
• Jvion: Jvion is a clinical AI vendor focused on risk stratification and patient-level predictive analytics using EHR and claims data for hospitals and health systems. It competes head-to-head with Reveal in surfacing at-risk patients ahead of clinical deterioration.
• ClosedLoop.ai: ClosedLoop builds healthcare-specific AI/ML platforms for risk prediction, population health, and value-based care, including CMS-approved models. It is a close peer in targeting ACOs and providers with AI-driven early identification workflows.
• Mendel (Mendel Health): Mendel applies AI to clinical and biomedical data to identify patient cohorts and accelerate research and clinical workflows. It overlaps with Lucem's Disease Insights and Accelerate Program capabilities for life sciences customer identification.

Broad incumbents

• Health Catalyst: Health Catalyst is a large healthcare data and analytics platform with AI-augmented clinical and operational analytics deployed across health systems. It is a broader incumbent competitor that can bundle AI risk models with its enterprise data warehouse.
• Tempus Labs: Tempus is a large clinical AI company combining molecular data with AI-driven insights for providers and life sciences. It overlaps with Lucem's life sciences commercialization motion and competes for the same health system and pharma budgets.
• LeanTaas: LeanTaas provides AI-driven analytics and operational solutions for hospitals and health systems, including capacity, staffing, and patient flow. It competes with Lucem for AI budget within enterprise healthcare buyers, albeit with an operations rather than clinical-disease focus.

Emerging players

• Deep 6 AI: Deep 6 AI uses AI on EHR data to find eligible patients for clinical trials and care programs. It overlaps with Lucem's patient identification wedge, particularly for life sciences trial acceleration use cases adjacent to Accelerate.
• Iterative Health: Iterative Health applies AI to gastroenterology imaging and clinical workflows. It is an adjacent emerging player that deepens AI in a single specialty (GI), illustrating the depth-versus-breadth trade-off Lucem faces across its multi-disease Reveal portfolio.

Others

• H1 (H1.co): H1 is a healthcare data platform connecting life sciences companies to providers, clinicians, and patient populations. It is a thematically related ecosystem participant for Lucem's life sciences commercialization motion, though not a direct AI diagnostic competitor.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/lucemhealth
• Facebookfacebook.com/LucemHealthTM
• LinkedInlinkedin.com/company/lucem-health

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucem Health